Ascendis Pharma A/S (ASND)
243.37
+0.38
(+0.16%)
USD |
NASDAQ |
Oct 23, 16:00
243.25
-0.12
(-0.05%)
After-Hours: 20:00
Ascendis Pharma Enterprise Value : 15.57B for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | 15.57B |
| October 22, 2026 | 15.54B |
| October 21, 2026 | 15.28B |
| October 20, 2026 | 14.98B |
| October 19, 2026 | 14.69B |
| October 16, 2026 | 14.38B |
| October 15, 2026 | 14.47B |
| October 14, 2026 | 14.49B |
| October 13, 2026 | 14.24B |
| October 12, 2026 | 14.49B |
| October 09, 2026 | 14.64B |
| October 08, 2026 | 14.21B |
| October 07, 2026 | 14.59B |
| October 06, 2026 | 14.43B |
| October 05, 2026 | 14.56B |
| October 02, 2026 | 14.55B |
| October 01, 2026 | 14.51B |
| September 30, 2026 | 14.55B |
| September 29, 2026 | 14.56B |
| September 28, 2026 | 14.69B |
| September 25, 2026 | 14.40B |
| September 24, 2026 | 14.74B |
| September 23, 2026 | 14.24B |
| September 22, 2026 | 15.19B |
| September 21, 2026 | 15.19B |
| Date | Value |
|---|---|
| September 18, 2026 | 15.13B |
| September 17, 2026 | 15.28B |
| September 16, 2026 | 15.85B |
| September 15, 2026 | 15.33B |
| September 14, 2026 | 16.98B |
| September 11, 2026 | 16.89B |
| September 10, 2026 | 16.74B |
| September 09, 2026 | 16.71B |
| September 08, 2026 | 17.32B |
| September 04, 2026 | 17.35B |
| September 03, 2026 | 17.39B |
| September 02, 2026 | 17.14B |
| September 01, 2026 | 16.68B |
| August 31, 2026 | 16.86B |
| August 28, 2026 | 15.87B |
| August 27, 2026 | 15.96B |
| August 26, 2026 | 16.02B |
| August 25, 2026 | 16.20B |
| August 24, 2026 | 16.13B |
| August 21, 2026 | 16.22B |
| August 20, 2026 | 16.32B |
| August 19, 2026 | 16.64B |
| August 18, 2026 | 15.93B |
| August 17, 2026 | 15.83B |
| August 14, 2026 | 15.91B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| BioMarin Pharmaceutical, Inc. | 14.17B |
| Novo Nordisk A/S | 145.21B |
| Evaxion AS | 24.46M |
| Genmab A/S | 29.91B |
| Zealand Pharma A/S | 216.96M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 240.65M |
| Revenue (Quarterly) | 394.49M |
| Total Expenses (Quarterly) | 153.84M |
| EPS Diluted (Quarterly) | 3.522 |
| Gross Profit Margin (Quarterly) | 90.64% |
| Profit Margin (Quarterly) | 61.00% |
| Earnings Yield | 5.39% |
| Operating Earnings Yield | 0.81% |
| Normalized Earnings Yield | 5.393 |